Zhijun Li

Dr. Zhijun Li


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

5 April 2022 in BMC Neurology
Verified
Journal Article
Open access
PDF file
JXJun Xiao
Jun Xiao
PFPei-Cai Fu
Pei-Cai Fu
ZLZhijun Li
Zhijun Li
Background: To report the main spectrum and new clinical and imaging characteristics of dipeptidyl-peptidase-like protein 6 (DPPX) antibody-associated encephalitis, and to evaluate the effect of immunotherapy. Methods: A retrospective analysis of nine patients with anti-DPPX encephalitis was performed, and all previously reported cases in the literature were reviewed. A cell-based indirect immunofluorescence assay using human embryonic kidney 293 cells transfected with DPPX was used. Results: Nine patients were identified (median age, 51 years; range, 14–65 years) with prodromal fever, diarrhea, or weight loss, followed by rapid progressive encephalopathy characterized by cognitive disorder. One patient who received methylprednisolone therapy and a trial of tacrolimus showed substantial improvement and had no relapse by the 6-month follow-up. Our comprehensive literature review demonstrated that 53 cases were reported, of which more than half had prodromal weight loss (52.8%) and gastrointestinal disorders (58.5%). Cognitive disorders (74.6%) and brainstem/spinal cord disorders (75.5%) were the most common major symptoms. A greater proportion of Chinese patients than non-Chinese patients had abnormalities on brain magnetic resonance imaging specific for encephalitis (70.0% vs. 23.3%, P < 0.001). Our study is the first to report three patients with anti-DPPX encephalitis who had sleep disorders with rapid eye movement sleep behavior disorder, limb paralysis (two), severe pleocytosis, elevated protein levels (two) in the cerebrospinal fluid, and increased T2/FLAIR signal abnormalities in the bilateral hippocampus, temporal lobe, amygdala, basal ganglia, thalamus, centrum semiovale, and frontal and parietal lobes in seven patients (77.8%). Conclusion: Our study expands the clinical and imaging phenotypes of anti-DPPX encephalitis. Further studies elucidating the entire clinical spectrum of anti-DPPX encephalitis, its pathogenic mechanisms, and prognosis under long-term immunosuppressive therapy are warranted.

1 January 2024 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
JLJing Lin
Jing Lin
YLYue Li
Yue Li
MGMengcui Gui
Mengcui Gui
BBBitao Bu
Bitao Bu
ZLZhijun Li
Zhijun Li
Background: Refractory generalized myasthenia gravis (GMG) remains a substantial therapeutic challenge. Telitacicept, a recombinant human B-lymphocyte stimulator receptor-antibody fusion protein, holds promise for interrupting the immunopathology of this condition. Objectives: This study retrospectively assessed the effectiveness and safety of telitacicept in patients with refractory GMG. Design: A single-center retrospective study. Methods: Patients with refractory GMG receiving telitacicept (160 mg/week or biweekly) from January to September in 2023 were included. We assessed effectiveness using Myasthenia Gravis Foundation of America post-intervention status (MGFA-PIS), myasthenia gravis treatment status and intensity (MGSTI), quantitative myasthenia gravis (QMG), and MG-activity of daily living (ADL) scores, alongside reductions in prednisone dosage at 3- and 6-month intervals. Safety profiles were also evaluated. Results: Sixteen patients with MGFA class II–V refractory GMG were included, with eight females and eight males. All patients were followed up for at least 3 months, and 11 patients reached 6 months follow-up. At the 3-month evaluation, 75% (12/16) demonstrated clinical improvement with MGFA-PIS. One patient achieved pharmacological remission, two attained minimal manifestation status, and nine showed functional improvement; three remained unchanged, and one deteriorated. By the 6-month visit, 90.1% (10/11) sustained significant symptomatic improvement. MGSTI scores and prednisone dosages significantly reduced at both follow-ups ( p < 0.05). MG-ADL and QMG scores showed marked improvement at 6 months ( p < 0.05). The treatment was well tolerated, with no severe adverse events such as allergy or infection reported. Conclusion: Our exploratory investigation suggests that telitacicept is a feasible and well-tolerated add-on therapy for refractory GMG, offering valuable clinical evidence for this novel treatment option.

2 March 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
QZQing Zhang
Qing Zhang
JLJing Lin
Jing Lin
MYMengge Yang
Mengge Yang
ZLZhijun Li
Zhijun Li
MZMin Zhang
Min Zhang
BBBi-Tao Bu
Bi-Tao Bu
Natural killer (NK) cells, a major component of the innate immune system, have prominent immunoregulatory, antitumor proliferation, and antiviral activities. NK cells act as a double-edged sword with therapeutic potential in neurological autoimmunity. Emerging evidence has identified NK cells are involved in the development and progression of neuroimmunological diseases such as multiple sclerosis, neuromyelitis optica spectrum disorders, autoimmune encephalitis, Guillain-Barré Syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, and idiopathic inflammatory myopathy. However, the regulatory mechanisms and functional roles of NK cells are highly variable in different clinical states of neuroimmunological diseases and need to be further determined. In this review, we summarize the evidence for the heterogenic involvement of NK cells in the above conditions. Further, we describe cutting-edge NK-cell-based immunotherapy for neuroimmunological diseases in preclinical and clinical development and highlight challenges that must be overcome to fully realize the therapeutic potential of NK cells.

10 June 2026 in Neurology and Therapy
Verified
Journal Article
Open access
YLYue Li
Yue Li
HYHuan Yang
Huan Yang
STSong Tan
Song Tan
LLLijun Luo
Lijun Luo
XCXuebing Cao
Xuebing Cao
ZLZhijun Li
Zhijun Li
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder needing long-term immunosuppressive therapy. Eculizumab is a promising treatment, but real-world evidence on its efficacy and safety is limited. This retrospective cohort study across six medical centers enrolled 60 patients with MG on eculizumab. Clinical data, including MG-Activities of Daily Living (MG-ADL) scores, quantitative MG scores (QMG), and oral corticosteroid dosage at baseline, weeks 1, 4, and 8, and final follow-up were obtained. Outcomes included score changes, post-intervention status (PIS), and safety profile. By week 8, 30.95% of patients achieved minimal manifestation status (MMS) or better, increasing to 32.69% at final follow-up. Mean ADL scores significantly dropped from 8.18 ± 3.99 at baseline to 5.59 ± 3.72 at week 1, 3.78 ± 3.42 at week 4, 3.50 ± 2.92 at week 8, and 3.33 ± 3.56 during final follow-up (p < 0.0001). Clinically meaningful improvement (CMI) was observed in 56.9%, 70.0%, 85.0%, and 76.27% at the respective time points. Both thymoma-associated and non-thymoma subgroups showed significant ADL improvement (p ≤ 0.026) with mixed-effects modeling revealing significant group × time interaction (p = 0.01).The thymoma-associated MG (TAMG) group had a faster initial response, with subsequent outcomes comparable between the two groups. Among the 37 patients (61.67%) who switched from FcRn inhibitor therapy to eculizumab, clinical outcomes were non-inferior to those of direct eculizumab recipients and the magnitude of MG-ADL improvement was comparable to that of the overall treatment group. The mean daily corticosteroid dose decreased from 21.21 ± 13.68 mg at baseline to 13.32 ± 10.42 mg at final follow-up (p < 0.0001) Adverse events were rare, with no treatment-related serious events. Eculizumab provides rapid and sustained clinical improvement in patients with MG, with a favorable safety profile. Patients with TAMG show a faster initial response. For patients with an inadequate response to FcRn inhibitors, eculizumab remains an effective rescue strategy.

13 September 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
QZQing Zhang
Qing Zhang
XHXingyu Han
Xingyu Han
ZBZhuajin Bi
Zhuajin Bi
MYMengge Yang
Mengge Yang
JLJing Lin
Jing Lin
BBBi-Tao Bu
Bi-Tao Bu
Introduction: NK cells are dysfunctional in myasthenia gravis (MG), but the mechanism is unclear. This study aims to measure associations and underlying mechanisms between the NK cells and the development of MG.Methods: Twenty healthy controls (HCs) and 53 MG patients who did not receive glucocorticoids and immunosuppressants were collected. According to the Myasthenia Gravis Foundation of America (MGFA) classification, MG patients were categorized into MGFA I group (n = 18) and MGFA II-IV group (n = 35). Flow cytometry, cell sorting, ELISA, mRNA-sequencing, RT-qPCR, western blot, and cell culture experiments were performed to evaluate the regulatory mechanism of exhausted NK cells.Results: Peripheral NK cells in MGFA II-IV patients exhibit exhausted phenotypes than HCs, marked by the dramatic loss of total NK cells, CD56dimCD16− NK cells, elevated PD1 expression, reduced NKG2D expression, impaired cytotoxic activity (perforin, granzyme B, CD107a) and cytokine secretion (IFN-γ). Plasma IL-6 and IL-21 are elevated in MG patients and mainly derived from the aberrant expansion of monocytes and Tfh cells, respectively. IL-6/IL-21 cooperatively induced NK-cell exhausted signature via upregulating SOCS2 and inhibiting the phosphorylation of STAT5. SOCS2 siRNA and IL-2 supplement attenuated the IL-6/IL-21-mediated alteration of NK-cell phenotypes and function.Discussion: Inhibition of IL-6/IL-21/SOCS2/STAT5 pathway and recovery of NK-cell ability to inhibit autoimmunity may be a new direction in the treatment of MG.